ANTX AN2 Therapeutics, Inc.
Nasdaq · SEC CIK 1880438 · EDGAR
- Bought, last 12 months
- $11.6K 1 purchases by 1 insiders
- Sold, last 12 months
- $398.2K 13 sales by 6 insiders
- Filings on record
- 190 since 2022-03-31, latest 2026-09-16 17:35
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Readnour Robin Shane | Dir | — | $316.7K |
| Eizen Joshua M | See Remarks | — | $52.9K |
| FitzPatrick Margaret M | Dir | $11.6K | — |
| Chanda Sanjay | Chief Development Off | — | $9,311 |
| Day Lucy | CFO | — | $8,862 |
| Prior Stephen David | Chief Strategy Off | — | $7,363 |
| Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| Trenor Cameron C. III | Chief Medical Off | — | — |
| Marks Gilbert Lynn | Dir | — | — |
| Martin Patricia A. | Dir | — | — |
Transactions 139
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-16 17:35 | 2026-09-15 | ANTX | Trenor Cameron C. III | Chief Medical Off | A - Grant | $0.00 | +116.7K | 116.7K | New | $0 |
| MTI | 2026-09-11 19:45 | 2026-09-09 | ANTX | Readnour Robin Shane | Dir | S - Sale | $6.02 | -1,108 | 624.8K | -0.2% | -$6,675 |
| MTI | 2026-09-08 19:42 | 2026-09-03+ | ANTX | Readnour Robin Shane | Dir | S - Sale | $6.04 | -16.1K | 625.4K | -3% | -$97.3K |
| 2026-09-04 16:25 | 2026-09-01 | ANTX | Williams Sarah Joanne | Principal Accounting Off | S - Sale | $5.53 | -272 | 66.3K | -0.4% | -$1,504 | |
| 2026-09-02 18:43 | 2026-09-01 | ANTX | FitzPatrick Margaret M | Dir | P - Purchase | $5.53 | +2,098 | 10.7K | +24% | +$11.6K | |
| MTI | 2026-08-19 17:58 | 2026-08-17 | ANTX | Readnour Robin Shane | Dir | S - Sale | $6.01 | -35.4K | 633.9K | -5% | -$212.7K |
| I | 2026-08-14 14:12 | 2026-08-14 | ANTX | Zakrzewski Joseph S | Dir | G - Gift | $0.00 | -405.9K | 0 | -100% | $0 |
| 2026-07-10 19:41 | 2026-07-10 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +2,852 | 59.1K | +5% | $0 | |
| 2026-07-10 19:41 | 2026-07-10 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +2,789 | 81.9K | +4% | $0 | |
| 2026-07-10 19:40 | 2026-07-10 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +766 | 18.9K | +4% | $0 | |
| 2026-07-10 18:15 | 2026-07-08 | ANTX | Eizen Joshua M | See Remarks | S - Sale | $4.17 | -5,945 | 206.6K | -3% | -$24.8K | |
| 2026-06-02 16:31 | 2026-05-29 | ANTX | Williams Sarah Joanne | Principal Accounting Off | S - Sale | $4.43 | -265 | 66.6K | -0.4% | -$1,174 | |
| 2026-04-10 20:58 | 2026-04-10 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +3,775 | 56.3K | +7% | $0 | |
| 2026-04-10 20:53 | 2026-04-10 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +3,775 | 79.1K | +5% | $0 | |
| 2026-04-10 20:51 | 2026-04-10 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +1,192 | 18.1K | +7% | $0 | |
| 2026-03-05 | 2026-03-03 | ANTX | Williams Sarah Joanne | Principal Accounting Off | S - Sale | $1.06 | -327 | 66.8K | -0.5% | -$346.62 | |
| D | 2026-02-23 | 2026-02-20 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +112.2K | 368.6K | +44% | $0 |
| D | 2026-02-23 | 2026-02-20 | ANTX | Day Lucy | CFO | A - Grant | $0.00 | +38.0K | 118.4K | +47% | $0 |
| D | 2026-02-23 | 2026-02-20 | ANTX | Chanda Sanjay | Chief Development Off | A - Grant | $0.00 | +38.0K | 118.8K | +47% | $0 |
| 2026-02-23 | 2026-02-20 | ANTX | Williams Sarah Joanne | Principal Accounting Off | A - Grant | $0.00 | +48.4K | 67.2K | +257% | $0 | |
| D | 2026-02-23 | 2026-02-20 | ANTX | Eizen Joshua M | See Remarks | A - Grant | $0.00 | +50.0K | 207.5K | +32% | $0 |
| 2026-01-14 | 2026-01-12 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +11.6K | 75.3K | +18% | $0 | |
| 2026-01-14 | 2026-01-12 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +11.6K | 52.5K | +28% | $0 | |
| 2026-01-14 | 2026-01-12 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +3,650 | 16.9K | +28% | $0 | |
| M | 2026-01-07 | 2026-01-05+ | ANTX | Day Lucy | CFO | S - Sale | $1.01 | -8,807 | 75.4K | -10% | -$8,862 |
| M | 2026-01-07 | 2026-01-05+ | ANTX | Eizen Joshua M | See Remarks | S - Sale | $1.00 | -24.9K | 159.4K | -13% | -$24.9K |
| M | 2026-01-07 | 2026-01-05+ | ANTX | Prior Stephen David | Chief Strategy Off | S - Sale | $1.00 | -6,462 | 59.1K | -10% | -$6,491 |
| M | 2026-01-07 | 2026-01-05+ | ANTX | Chanda Sanjay | Chief Development Off | S - Sale | $1.01 | -9,251 | 75.8K | -11% | -$9,311 |
| 2025-11-06 | 2025-11-04 | ANTX | Eizen Joshua M | See Remarks | S - Sale | $1.14 | -2,819 | 177.4K | -2% | -$3,214 | |
| 2025-11-06 | 2025-11-04 | ANTX | Prior Stephen David | Chief Strategy Off | S - Sale | $1.14 | -765 | 65.5K | -1% | -$872.10 | |
| 2025-10-14 | 2025-10-10 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +10.4K | 63.7K | +19% | $0 | |
| 2025-10-14 | 2025-10-10 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +10.4K | 40.9K | +34% | $0 | |
| 2025-10-14 | 2025-10-10 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +3,274 | 13.3K | +33% | $0 | |
| 2025-07-11 | 2025-07-10 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +11.9K | 30.6K | +64% | $0 | |
| 2025-07-11 | 2025-07-10 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +11.9K | 53.4K | +29% | $0 | |
| 2025-07-11 | 2025-07-10 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +3,750 | 9,981 | +60% | $0 | |
| I | 2025-06-16 | 2025-05-28 | ANTX | Leonard Braden Michael | 10% | S - Sale | $1.09 | -200.0K | 3.02M | -6% | -$218.0K |
| 2025-06-03 | 2025-06-02 | ANTX | Easom Eric | CEO, Dir | P - Purchase | $1.07 | +10.0K | 256.4K | +4% | +$10.7K | |
| MI | 2025-05-30 | 2025-05-28+ | ANTX | Leonard Braden Michael | 10% | S - Sale | $1.13 | -2.53M | 3.22M | -44% | -$2.87M |
| 2025-05-29 | 2025-05-28 | ANTX | FitzPatrick Margaret M | Dir | P - Purchase | $1.18 | +8,610 | 8,610 | New | +$10.2K | |
| 2025-04-11 | 2025-04-10 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +3,065 | 6,231 | +97% | $0 | |
| 2025-04-11 | 2025-04-10 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +9,705 | 41.5K | +31% | $0 | |
| 2025-04-11 | 2025-04-10 | ANTX | Zakrzewski Joseph S | Dir | A - Grant | $0.00 | +10.5K | 145.5K | +8% | $0 | |
| 2025-04-11 | 2025-04-10 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +9,705 | 18.7K | +108% | $0 | |
| D | 2025-02-28 | 2025-02-26 | ANTX | Eizen Joshua M | See Remarks | A - Grant | $0.00 | +58.5K | 175.2K | +50% | $0 |
| D | 2025-02-28 | 2025-02-26 | ANTX | Prior Stephen David | Chief Strategy Off | A - Grant | $0.00 | +28.0K | 61.3K | +84% | $0 |
| D | 2025-02-28 | 2025-02-26 | ANTX | Day Lucy | CFO | A - Grant | $0.00 | +46.5K | 79.2K | +142% | $0 |
| D | 2025-02-28 | 2025-02-26 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +145.2K | 246.4K | +144% | $0 |
| D | 2025-02-28 | 2025-02-26 | ANTX | Chanda Sanjay | Chief Development Off | A - Grant | $0.00 | +50.2K | 80.1K | +168% | $0 |
| 2025-01-07 | 2025-01-03 | ANTX | Prior Stephen David | Chief Strategy Off | S - Sale | $1.34 | -2,029 | 33.3K | -6% | -$2,719 | |
| 2025-01-07 | 2025-01-03 | ANTX | Eizen Joshua M | See Remarks | S - Sale | $1.34 | -9,663 | 116.7K | -8% | -$12.9K | |
| 2025-01-07 | 2025-01-03 | ANTX | Day Lucy | CFO | S - Sale | $1.34 | -2,957 | 32.7K | -8% | -$3,962 | |
| 2025-01-07 | 2025-01-03 | ANTX | Chanda Sanjay | Chief Development Off | S - Sale | $1.34 | -2,957 | 29.8K | -9% | -$3,962 | |
| 2024-12-23 | 2024-12-19 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +8,972 | 31.8K | +39% | $0 | |
| 2024-12-23 | 2024-12-19 | ANTX | Readnour Robin Shane | Dir | A - Grant | $0.00 | +9,077 | 9,077 | New | $0 | |
| 2024-12-23 | 2024-12-19 | ANTX | Zakrzewski Joseph S | Dir | A - Grant | $0.00 | +9,816 | 135.0K | +8% | $0 | |
| 2024-12-23 | 2024-12-19 | ANTX | Martin Patricia A. | Dir | A - Grant | $0.00 | +3,166 | 3,166 | New | $0 | |
| 2024-12-23 | 2024-12-19 | ANTX | Aziz Kabeer | Dir | A - Grant | $0.00 | +8,972 | 8,972 | New | $0 | |
| MI | 2024-12-10 | 2024-12-06+ | ANTX | Readnour Robin Shane | Dir | P - Purchase | $1.45 | +60.0K | 582.3K | +11% | +$86.8K |
| MI | 2024-11-27 | 2024-11-26+ | ANTX | Readnour Robin Shane | Dir | P - Purchase | $1.41 | +75.0K | 527.3K | +17% | +$105.8K |
| 2024-11-27 | 2024-11-27 | ANTX | Zakrzewski Joseph S | Dir | P - Purchase | $1.40 | +2,000 | 125.2K | +2% | +$2,800 | |
| MI | 2024-11-21 | 2024-11-19+ | ANTX | Readnour Robin Shane | Dir | P - Purchase | $1.06 | +200.0K | 585.1K | +52% | +$213.0K |
| M | 2024-11-20 | 2024-11-18+ | ANTX | Zakrzewski Joseph S | Dir | P - Purchase | $1.00 | +25.0K | 118.2K | +27% | +$25.1K |
| I | 2024-11-18 | 2024-11-18 | ANTX | Easom Eric | CEO, Dir | P - Purchase | $1.00 | +50.0K | 1.07M | +5% | +$50.0K |
| D | 2024-11-05 | 2024-11-04 | ANTX | Eizen Joshua M | See Remarks | A - Grant | $0.00 | +31.5K | 126.3K | +33% | $0 |
| D | 2024-11-05 | 2024-11-04 | ANTX | Prior Stephen David | Chief Strategy Off | A - Grant | $0.00 | +10.1K | 35.3K | +40% | $0 |
| I | 2024-08-14 | 2024-08-14 | ANTX | Leonard Braden Michael | 10% | P - Purchase | $1.04 | +1.50M | 5.75M | +35% | +$1.56M |
| MI | 2024-08-13 | 2024-08-09 | ANTX | RA Capital Healthcare Fund LP | 10% | S - Sale | $1.08 | -3.53M | 1.73M | -67% | -$3.81M |
| 2024-07-12 | 2024-07-10 | ANTX | Eizen Joshua M | CLO | A - Grant | $0.00 | +60.0K | 94.8K | +172% | $0 | |
| A | 2024-03-29 | 2024-03-15 | ANTX | Chanda Sanjay | Chief Development Off | A - Grant | $0.00 | +27.5K | 28.2K | +3,741% | $0 |
| A | 2024-03-29 | 2024-03-15 | ANTX | Krause Kevin Michael | Chief Strategy Off | A - Grant | $0.00 | +30.0K | 31.9K | +1,567% | $0 |
| A | 2024-03-29 | 2024-03-15 | ANTX | Day Lucy | CFO | A - Grant | $0.00 | +27.5K | 30.6K | +879% | $0 |
| A | 2024-03-29 | 2024-03-15 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +99.0K | 101.1K | +4,648% | $0 |
| A | 2024-03-29 | 2024-03-15 | ANTX | Eckburg Paul | Chief Medical Off | A - Grant | $0.00 | +30.0K | 51.4K | +140% | $0 |
| A | 2024-03-29 | 2024-03-15 | ANTX | Eizen Joshua M | CLO | A - Grant | $0.00 | +30.0K | 32.4K | +1,226% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +99.0K | 101.1K | +4,648% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Chanda Sanjay | Chief Development Off | A - Grant | $0.00 | +27.5K | 28.2K | +3,741% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Krause Kevin Michael | Chief Strategy Off | A - Grant | $0.00 | +30.0K | 31.9K | +1,567% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Day Lucy | CFO | A - Grant | $0.00 | +27.5K | 30.6K | +879% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Eizen Joshua M | CLO | A - Grant | $0.00 | +30.0K | 32.4K | +1,226% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Eckburg Paul | Chief Medical Off | A - Grant | $0.00 | +30.0K | 51.4K | +140% | $0 |
| I | 2024-01-19 | 2024-01-18 | ANTX | Zakrzewski Joseph S | Dir | S - Sale | $19.11 | -100.0K | 405.9K | -20% | -$1.91M |
| I | 2024-01-18 | 2024-01-16 | ANTX | Adjuvant Capital Management, LLC | 10% | S - Sale | $19.65 | -15.9K | 377.5K | -4% | -$312.6K |
| 2024-01-18 | 2024-01-16 | ANTX | Adjuvant Capital Management, LLC | 10% | S - Sale | $19.65 | -84.1K | 2.00M | -4% | -$1.65M | |
| MI | 2024-01-18 | 2024-01-16 | ANTX | Aziz Kabeer | Dir | S - Sale | $19.65 | -100.0K | 377.5K | -21% | -$1.96M |
| MI | 2024-01-17 | 2024-01-12 | ANTX | Readnour Robin Shane | Dir | S - Sale | $21.91 | -1,425 | 485.1K | -0.3% | -$31.2K |
| MI | 2024-01-12 | 2024-01-10 | ANTX | Readnour Robin Shane | Dir | S - Sale | $21.93 | -3,669 | 485.8K | -0.7% | -$80.4K |
| DMT | 2024-01-11 | 2024-01-09 | ANTX | Krause Kevin Michael | Chief Strategy Off | M - OptEx | $4.59 | +7,417 | 9,331 | +388% | +$34.0K |
| DT | 2024-01-11 | 2024-01-09 | ANTX | Krause Kevin Michael | Chief Strategy Off | S - Sale+OE | $20.14 | -7,417 | 1,914 | -79% | -$149.4K |
| T | 2024-01-04 | 2024-01-02 | ANTX | Easom Eric | CEO, Dir | S - Sale | $20.09 | -2,777 | 2,130 | -57% | -$55.8K |
| DT | 2024-01-04 | 2024-01-02 | ANTX | Krause Kevin Michael | Chief Strategy Off | M - OptEx | $0.42 | +2,583 | 4,497 | +135% | +$1,085 |
| DT | 2024-01-04 | 2024-01-02 | ANTX | Krause Kevin Michael | Chief Strategy Off | S - Sale+OE | $20.12 | -2,583 | 1,914 | -57% | -$52.0K |
| TI | 2023-11-16 | 2023-11-14 | ANTX | Adjuvant Capital Management, LLC | 10% | S - Sale | $16.15 | -288 | 393.4K | -0.1% | -$4,651 |
| T | 2023-11-16 | 2023-11-14 | ANTX | Adjuvant Capital Management, LLC | 10% | S - Sale | $16.15 | -1,522 | 2.08M | -0.1% | -$24.6K |
| MTI | 2023-11-16 | 2023-11-14 | ANTX | Aziz Kabeer | Dir, 10% | S - Sale | $16.15 | -1,810 | 2.08M | -0.1% | -$29.2K |
| MI | 2023-10-03 | 2023-09-29+ | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | S - Sale | $16.27 | -16.7K | 394.6K | -4% | -$271.1K |
| M | 2023-10-03 | 2023-09-29+ | ANTX | Adjuvant Global Health Technology Fund, L.P. | 10% | S - Sale | $16.27 | -88.1K | 2.09M | -4% | -$1.43M |
| MI | 2023-10-03 | 2023-09-29+ | ANTX | Aziz Kabeer | Dir, 10% | S - Sale | $16.27 | -104.8K | 2.08M | -5% | -$1.70M |
| MI | 2023-09-29 | 2023-09-27+ | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | S - Sale | $16.11 | -1,490 | 410.4K | -0.4% | -$24.0K |
| M | 2023-09-29 | 2023-09-27+ | ANTX | Adjuvant Global Health Technology Fund DE, L.P. | 10% | S - Sale | $16.11 | -7,867 | 2.18M | -0.4% | -$126.7K |
Purchase Sale Sale after option exercise All abbreviations